Andrew Davis, MD

Medical Oncologist

Andrew Davis

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Video thumbnail for Andrew Davis, MD

Watch video on YouTube

Andrew Davis, MD

3 mins

Washington University medical oncologist Andrew Davis, MD, discusses what breast cancer patients can expect from their extended care team at Siteman Cancer Center. Learn more about Dr. Davis: https://siteman.wustl.edu/doctor/davis-andrew/

Learn more about the Siteman Approach to Breast Cancer: https://siteman.wustl.edu/treatment/cancer-types/breast-cancer/our-approach/

Learn more about all breast cancer treatment options at Siteman Cancer Center: https://siteman.wustl.edu/treatment/cancer-types/breast-cancer/treatments/

Hear from Siteman patients who discuss their journey with breast cancer diagnosis, treatment and recovery: https://siteman.wustl.edu/treatment/cancer-types/breast-cancer/patient-stories/

Clinical Expertise

Primary Academic Title

Associate Professor of Medicine, Division of Medical Oncology, WashU Medicine

Board Certification

  • 2017: American Board of Internal Medicine
  • 2020: American Board of Internal Medicine, Hematology
  • 2020: American Board of Internal Medicine, Medical Oncology

Training

  • 2014 - 2017: Resident, Internal Medicine, Northwestern University Chicago, Chicago, IL
  • 2017 - 2020: Fellow, Hematology and Oncology, Northwestern University, Evanston, IL

Education

  • 2014: MD, Northwestern University, Chicago, IL

Research & Selected Publications

Research Interest

Liquid biopsies, predictive biomarkers, novel therapeutics

Research Publications

Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic value
Authors:

Reduzzi C, Nicolò E, Gerratana L, one or more additional authors omitted Davis AA, one or more additional authors omitted Cristofanilli M

Journal & Year:

Sci Transl Med | 2026

Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity
Authors:

Davis AA, Jaeger E, Hagemann IS, one or more additional authors omitted Cristofanilli M

Journal & Year:

Clin Cancer Res | 2025

Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Authors:

Ademuyiwa FO, Ma CX, Weilbaecher K, one or more additional authors omitted Davis A

Journal & Year:

Clin Cancer Res | 2025

Novel treatment approaches utilizing antibody-drug conjugates in breast cancer
Authors:

Davis AA, Hesse J, Pereira PMR, Ma CX

Journal & Year:

NPJ Breast Cancer | 2025

Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer
Authors:

Podany EL, Foffano L, Gerratana L, one or more additional authors omitted Davis AA

Journal & Year:

JAMA Netw Open | 2025

Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resista…
Authors:

Gerratana L, Davis AA, Foffano L, one or more additional authors omitted Cristofanilli M

Journal & Year:

Cancer Lett | 2025

Reporting of immune-related adverse events in US Food and Drug Administration approvals of immune checkpoint inhibitors
Authors:

Tapiavala S, Luo C, Shenouda M, Patel V, Davis AA

Journal & Year:

Front Oncol | 2025

ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer
Authors:

Schneider BP, Zhao F, Ballinger TJ, one or more additional authors omitted Davis AA, one or more additional authors omitted Wolff AC

Journal & Year:

J Clin Oncol | 2024